Therapy of psoriasis using topical glucocorticosteroids

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The article provides an overview of studies on the use of topical glucocorticosteroids (TGCS) in psoriasis. It is noted that TGCS have anti-inflammatory, antipruritic, immunosuppressive, vasoconstrictive and antiproliferative effects, which is important in the treatment of psoriasis. Most studies have shown that TGCS such as betamethasone, mometasone, alclomethasone and clobetazol shampoo are the first-line drugs for the treatment of mild to moderate psoriasis. It has been established that currently, for the treatment of psoriasis, it is preferable to use combined drugs betamethasone + calcipotriol, which allow for long-term control of the disease while following strict recommendations for their use. Salicylic acid and zinc pyrithione may be recommended to accelerate the regression of psoriasis. Nanotechnologies of the TGCS delivery system are being developed in order to increase their bioavailability.

About the authors

T. V. Potupchik

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: potupchik_tatyana@mail.ru
ORCID iD: 0000-0003-1133-4447
SPIN-code: 8353-3513

Candidate of Medical Sciences

Russian Federation, Krasnoyarsk

E. V. Kapustina

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia; Krasnoyarsk Regional Clinical Hospital

Email: potupchik_tatyana@mail.ru
ORCID iD: 0000-0001-9528-2781
SPIN-code: 3716-9832

Сandidate of Medical Sciences

Russian Federation, Krasnoyarsk; Krasnoyarsk

P. А. Shesternya

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Email: potupchik_tatyana@mail.ru
ORCID iD: 0000-0001-8652-1410
SPIN-code: 6527-8762

MD, Professor

Russian Federation, Krasnoyarsk

E. V. Turchik

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Email: potupchik_tatyana@mail.ru
ORCID iD: 0009-0006-9805-9060
SPIN-code: 5376-7695
Russian Federation, Krasnoyarsk

A. M. Kucherenko

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Email: potupchik_tatyana@mail.ru
ORCID iD: 0000-0002-9158-4536
Russian Federation, Krasnoyarsk

A. K. Tokmalaev

Peoples’ Friendship University of Russia named after Patrice Lumumba

Email: potupchik_tatyana@mail.ru
ORCID iD: 0000-0001-7046-0799
SPIN-code: 1650-0831

MD, Professor

Russian Federation, Moscow

References

  1. Elman S.A., Weinblatt M., Merola J.F. Targeted therapies for psoriatic arthritis: an update for the dermatologist. Semin Cutan Med Surg. 2018; 37 (3): 173–81. doi: 10.12788/j.sder.2018.045
  2. Yiu Z.Z., Warren R.B. Ustekinumab for the treatment of psoriasis: an evidence update. Semin Cutan Med Surg. 2018; 37 (3): 143–7. doi: 10.12788/j.sder.2018.040
  3. Yang E.J., Beck K.M., Sanchez I.M. et al. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl). 2018; 8: 41–7. doi: 10.2147/PTT.S169389
  4. Larsabal M., Ly S., Sbidian E. et al. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br J Dermatol. 2019; 180 (3): 647–56. doi: 10.1111/bjd.17147
  5. Nguyen C.T., Bloch Y., Składanowska K. et al. Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight. Clin Immunol. 2019; 206: 15–22. doi: 10.1016/j.clim.2018.09.002
  6. Белоусова Т.А., Каиль М.В. Терапевтические возможности наружных глюкокортикостероидов в современной клинической практике. Медицинский совет. 2020; 12: 36–45 [Belousova T.A., Kail M.V. Therapeutic possibilities of topical corticosteroids in modern clinical practice. Medical Council. 2020; 12: 36–45 (in Russ.)]. doi: 10.21518/2079-701X-2020-12-36-45
  7. Клейменова И.А., Есенин С.А. История создания и совершенствования топических стероидов. Дерматология. Приложение к журналу Concilium Medicum. 2011; 3: 14–6 [Kleimenova I.A., Yesenin S.A. History of the creation and improvement of topical steroids. Dermatology. Supplement to the journal Concilium Medicum. 2011; 3: 14–6 (in Russ.)].
  8. Скороходкина О.В., Зайнетдинова Г.М., Хакимова Р.Ф. Топические глюкокортикостероиды в лечении атопического дерматита у детей: результаты собственных наблюдений. Медицинский совет. 2023; 17 (2): 114–20 [Skorokhodkina O.V., Zaynetdinova G.M., Khakimova R.F. Atopic dermatitis management with topical corticosteroids in children: own observations. Medical Council. 2023; 17 (2): 114–20 (in Russ.)]. doi: 10.21518/ms2023-029
  9. Псориаз. Клинические рекомендации, 2023 [Psoriasis. Clinical Guidelines, 2023 (in Russ.)]. URL: cr.minzdrav.gov.ru/preview-cr/234_2
  10. Habet K.A., Kolli S.S., Pona A. et al. A review of topical corticosteroid sprays for the treatment of inflammatory dermatoses. Dermatol Online J. 2019; 25 (8): 13030/qt0855j2zz.
  11. Fowler J.F. Jr, Hebert A.A., Sugarman J. DFD-01, a novel medium potency betamethasone dipropionate 0,05% emollient spray, demonstrates similar efficacy to augmented betamethasone dipropionate 0,05% lotion for the treatment of moderate plaque psoriasis. J Drugs Dermatol. 2016; 15 (2): 154–62.
  12. Sidgiddi S., Pakunlu R.I., Allenby K. Efficacy, safety, and potency of betamethasone dipropionate spray 0,05%: atreatment for adults with mild-to-moderate plaque psoriasis. J Clin Aesthet Dermatol. 2018; 11 (4): 14–22.
  13. Gold L.S., Bagel J., Allenby K. et al. Betamethasone dipropionate spray 0,05% alleviates troublesome symptoms of plaque psoriasis. Cutis. 2020; 105 (2): 97–102;E1.
  14. Lambert J., Hol C.W., Vink J. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study. J Eur Acad Dermatol Venereol. 2015; 29 (12): 2349–55. doi: 10.1111/jdv.13230
  15. Круглова Л.С., Мордовцева В.В., Жукова О.В. и др. Комбинация кальципотриола и бетаметазона в лечении псориаза. Клиническая дерматология и венерология. 2014; 12 (6): 54–63 [Kruglova L.S., Mordovtseva V.V., Zhukova O.V. et al. Combination of calcipotriol and betamethasone in psoriasis treatment. Russian Journal of Clinical Dermatology and Venereology. 2014; 12 (6): 54–63 (in Russ.)].
  16. Spada F., Barnes T.M., Greive K.A. et al. Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids. Australas J Dermatol. 2018; 59 (3): e168-e174. doi: 10.1111/ajd.12762
  17. Короткий Н.Г., Тихомиров А.А., Гамаюнов Б.Н. Оценка клинической эффективности современного стероида алклометазона дипропионата (Афлодерма) в наружной терапии атопического дерматита у детей. Клиническая дерматология и венерология. 2007; 6: 24–31 [Korotky N.G., Tikhomirov A.A., Gamayunov B.N. Evaluation of the clinical efficacy of the modern steroid alclomethasone dipropionate (Afloderm) in the external therapy of atopic dermatitis in children. Russian Journal of Clinical Dermatology and Venereolog. 2007; 6: 24–31 (in Russ.)].
  18. Fölster-Holst R., Abeck D., Torrelo A. Topical hydrocortisone 17-butyrate 21-propionate in the treatment of inflammatory skin diseases: pharmacological data, clinical efficacy, safety and calculation of the therapeutic index. Pharmazie. 2016; 71 (3): 115–21.
  19. Бакулев А.Л., Утц С.Р., Платонова А.Н. и др. Опыт применения шампуня клобетазола пропионата при псориазе волосистой части головы. Фарматека. 2015; S1: 49–53 [Bakulev A.L., Utts S.R., Platonova A.N. et al. The experience of using clobetazole propionate shampoo for psoriasis of the scalp. Farmateka. 2015; S1: 49–53 (in Russ.)].
  20. Jacobi A., Mayer A., Augustin M. Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review. Dermatol Ther (Heidelb). 2015; 5 (1): 1–18. doi: 10.1007/s13555-015-0068-3
  21. Faulk C.T., Pittelkow M.R., Feldman S.R. et al. The most powerful topical anti-inflammatory: the cautionary and enlightening story of SKIN-CAP. Dermatol Online J. 2024; 30 (6). doi: 10.5070/D330664682
  22. Khurana B., Arora D., Narang R. Topical delivery of nanoemulsion for antipsoriatic drugs. J Drug Deliv Ther. 2018; 8: 1–11. doi: 10.22270/jddt.v8i5-s.1914
  23. Palmer B.C., DeLouise L.A. Nanoparticle-enabled transdermal drug delivery systems for enhanced dose control and tissue targeting. Molecules. 2016; 21: 7–9. doi: 10.3390/molecules21121719
  24. Akhtar N., Verma A., Pathak K. Exploring preclinical and clinical effectiveness of nanoformulations in the treatment of atopic dermatitis: Safety aspects and patent reviews. Bulletin of Faculty of Pharmacy Cairo University. 2017; 55 (1): 1–10. doi: 10.1016/j.bfopcu.2016.12.003
  25. Shetty K., Sherje A.P. Nano intervention in topical delivery of corticosteroid for psoriasis and atopic dermatitis-a systematic review. J Mater Sci Mater Med. 2021; 32 (8): 88. doi: 10.1007/s10856-021-06558-y

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).